The potential of PDE4 inhibitors in asthma or COPD

Current Opinion in Investigational Drugs

Volumn 1, Issue 2, 2000, Pages 204-213

  Spina, D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Asthma; COPD; PDE4; Phosphodiesterase inhibitors

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; 6 (4 ACETAMIDOPHENYL) 1,2,3,4,4A,10B HEXAHYDRO 8,9 DIMETHOXY 2 METHYLBENZO[C][1,6]NAPHTHYRIDINE; 8 [[1 (3,4 DIMETHOXYPHENYL) 2 HYDROXYETHYL]AMINO] 3,7 DIHYDRO 7 (2 METHOXYETHYL) 1,3 DIMETHYL 1H PURINE 2,6 DIONE; ATIZORAM; BECLOMETASONE; BENZAFENTRINE; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CILOSTAZOL; CYCLIC AMP; CYCLIC GMP; ENPROFYLLINE; GLUCOCORTICOID; IBUDILAST; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; ROFLUMILAST; ROLIPRAM; THEOPHYLLINE; UNCLASSIFIED DRUG; ZARDAVERINE;

ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CELL FUNCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SYNTHESIS; HEADACHE; HUMAN; INFLAMMATORY CELL; NONHUMAN; REVIEW; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; LUNG DISEASES, OBSTRUCTIVE; PHOSPHODIESTERASE INHIBITORS;

EID: 0033761086     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents
2. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
3. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions
4. Phosphodiesterase inhibitors in the treatment of erectile dysfunction
5. Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis
6. Mapping the functional domains of human recombinant prosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding
7. Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activated protein kinase
8. Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities
9. Atomic structure of PDE4: Insights into phosphodiesterase mechanism a specificity
10. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3
11. Phosphorylation and activation of cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase
12. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5)
13. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE3D3 by phosphorylating it at Ser579
14. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases
15. The rat PDE3/IVd phosphodiesterase gene codes for muliple proteins differentially activated by cAMP-dependent protein kinase
16. In vitro differentiation of human monocytes to macrophages: Change of PDE profile and its relationship to suppression of tumor necrosis factor-alpha release by PDE inhibitors
17. Synergistic effects of interleukin 4 and interferon-γ on monocyte phosphodiesterase activity
18. Modulation of leukocyte cyclic AMP phosphodiesterase activity by recombinant interferon-gamma: Evidence for a differential effect on atopic monoyctes
19. Phospholipid regulation of a cyclic AMP-specific phosphodiesterase (PDE4) from U937 cells
20. Stereospecific binding of the antidepressnt rolipram to brain protein structures
21. Isolation of similar rolipram-inhibitable cyclic-AMP-specific phosphodiesterases from rat-barin and heart
22. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast
23. A low K(M), rolipram-sensitiv, cAMP-specific phosphodiesterase from human brain. Cloning ad expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of messenger-RNA
24. Human phosphodiesterases 4A: Characterization of full-length and truncated enzymes expressed in COS cells
25. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer
26. 3H]R-(-)-rolipram binding by selective inhibitors
27. Conformational difference between PDE4 apoenzyme and haloenzyme
28. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high-affinity rolipram binding site
29. 3H]rolipram binding activity and their relationship to emesis in the ferret
30. 3H]rolipram binding
31. Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase
32. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer
33. Excitation of area postrema neurons by transmitters, peptides and cyclic nucleotides
34. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4
35. 1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma
36. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects
37. Ariflo(TM) (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic
38. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions
39. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B
40. Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: A novel class of potent and selective phosphodiesterase type 4D inhibitors
41. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice
42. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D
43. Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: Involvement of endogenously released corticosterone and catecholamines
44. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement and affect
45. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms
46. Leukocyte and lymphocyte cyclic AMP responses in atopic eczema
47. Impaired lymphocyte cyclic adenosine monophosphate responses in atopic eczema
48. Heterologous desensitization of leukocytes: A possible mechanism of β adrenergic blockade in atopic dermatitis
49. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: A possible mechanism for cyclic AMP-agonist hyporesponsiveness
50. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis
51. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: A comparative study
52. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis
53. Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: Tachyphylaxis after theophylline therapy
54. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis
55. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis
56. Ro 20-1724: An agent that significantly improves psoriatic lesions in double-blind clinical trials
57. The role of the adrenergic system in allergy and bronchial hyperreactivity
58. The β-adrenergic system and allergic bronchial asthma: Changes in lymphocyte β-adrenergic receptor number and adenylate cyclase activity after an allergen-induced asthmatic attack
59. Reduced responsiveness of adenylate cyclase in alveolar macrophages from patients with asthma
60. Stimulation of cyclic AMP production in human alveolar macrophages induced by inflammatory mediators and β-symphathicomimetic
61. Cyclic nucleotide phosphadiesterases from purified human CD4+ and CD8+ T lymphocytes
62. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects
63. Increased respiratory burst and phosphodiesterase activity in alveolar eosinophils in chronic eosinophilic pneumonia
64. A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects
65. Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leukocytes from patients with atopic dermatitis: Correlation with respiratory atopy
66. The granulocyte response to the phosphodiesterase inhibitor Ro-20-1724 in asthma
67. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors
68. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells
69. Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors
70. Identification and quantification of phosphodiesterase (PDE)4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects
71. The role of phosphodiesterase isoenzymes in health and in atopic disease
72. Mechanisms of eosinophil-associated inflammation
73. The role of lymphocytes in allergic disease
74. CD8+ T cell subsets and chronic obstructive pulmonary disease
75. Airway inflammation in chronic obstructive pulmonary disease
76. Asthma - From bronchoconstriction to airways inflammation and remodeling
77. Structural and inflammatory changes in COPD: A comparison with asthma
78. Pharmacology of anti-asthma xanthines
79. The effect of theophylline and enproofylline on allergen-induced bronchoconstriction
80. Theophylline inhibits early and late asthmatic reactions induced by allergens in asthmatic subjects
81. Theophylline does not inhibit allergen-induced increase in airway responsiveness to methacholine
82. Theophylline reduces histamine release during pollen-induced rhinitis
83. Protective effect of antiasthma drugs on late ashtmatic reactions and increased airway responsiveness induced by toluene diisocyanate in sensitized subjects
84. Theophylline - An immunomodulatory role in asthma?
85. Induction of suppressor T cells in asthmatic children by theophyline treatment
86. Effect of theophylline on the proportion and function of T-suppressor cells in asthmatic children
87. Theophylline induced non specific suppressor activity in human peripheral blood lymphocytes
88. Theophylline-induced alterations in cellular immunity in asthmatic patients
89. A prospective controlled clinical trial of aminophylline as an adjunctive immunosuppressive agent
90. Allergen-induced recruitment of bronchoalveolar helper (OKT4) and suppressor (OKT8) T-cells in asthma. Relative increases in OKT8 cells in single early responders compared with those in late-phase responders
91. Theophylline attenuation of airway responses to allergen: Comparison with cromylyn metered-dose inhaler
92. Effect of slow-release theophylline on nasal antigen challenge in subjects with allergic rhinitis
93. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma
94. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition
95. Apoptosis of eosinophils and lymphocytes in allergic inflammation
96. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics
97. Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: A placebo-controlled parallel group study
98. Theophylline induces a reduction in circulating interleukin-4 and interleukin-5 in atopic asthmatics
99. Need for theophylline in severe steroid-requiring asthmatics
100. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy
101. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis
102. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral lood mononuclear cells
103. Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells
104. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma
105. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma
106. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma
107. Apparent irrelevance of cyclic nucleotides to the relaxation of tracheal smooth muscle induced by theophylline
108. Stimulation of endogenous cathecholamine release by theophylline: A proposed additional mechanism of action for theophylline effects
109. Methyl xanthine phosphodiesterase inhibitors behave as prostaglandin antagonists in a perfused rat mesenteric artery preparation
110. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes - their potential utility in the therapy of asthma
111. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma
112. Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo
113. Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test
114. Effect of ibudilast: A novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma
115. Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen
116. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose
117. RP 73401 (a phosphodiesterase IV inhibitor) single doses not prevent allergen induced bronchoconstriction during the early phase reaction in asthmatics
118. SB 207499 (Ariflo(TM)), a second-generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma
119. Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks
120. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PED4) inhibitor SB 207499 (Ariflo) in the guinea pig
121. Phosphodiesterases: The journey toward therapeutics
122. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors
123. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation
124. Prolonged β adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B
125. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils
126. Expression and regulation of human and rat phosphodiesterase type IV isogenes
127. Phosphodiesterase expression in human epithelial cells
128. Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells